Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
phIL12 Gene Electrotransfer for Head and Neck Basal Cell Carcinoma
NCT05077033Phase 1Completed
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of interleukin-12 plasmid in basal cell carcinoma (BCC), sponsored by Institute of Oncology Ljubljana. Primary endpoints: Number of acute adverse events at 2 days, Number of adverse events 7 days after the treatment and 3 more. Started Sep 2021; status: completed.
02
Drugs
interleukin-12 plasmid
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT05077033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077033.